Advice You - Finance

Have you heard of VantageScore? This is the new type of credit scoring assessment being put in place by the

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

three major credit bureaus. Because so many complaints were coming in from consumers and corporations deal

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ng in credit alike, the three agencies began to see the merit of adjusting credit scores to be more meaningf

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

l and consistent.

One of the major issues faced by consumers and lenders was inequity among the three credi

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

t tracking agencies. Representatives from each worked together on VantageScore in order to ensure that credi

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

scores are the same for each person through each of the major reporting agencies. This gives companies eva

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

uating customers for credit-readiness the ability to trust in each of the three agencies. It also removes t

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

he need for companies to perform multiple credit checks on customers in order to determine an average credit

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

rating.

One of the major issues facing consumers, is that until all three agencies transfer to the new syst

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

m there will be come confusion in the actual reported scoring. Because the FICO system, currently in use, d

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

notes a well-established credit record with a score of around 780 those receiving a 990 might be shocked. On

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

the other hand, a FICO rating of 600 would be around 800 on the new scale. Reviewers of credit-worthiness

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ust be prepared to receive and interpret both types of scores in the transitional period.

As of today, comp

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

nies are able to purchase the VantageScore scores of potential credit customers. However, the three credit b

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ureaus will not begin distributing personal scores to creditors until late 2006.

Due to massive scale credi

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

reforms, this effort on the part of the executives from each of the credit reporting agencies is seen as a

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ositive move towards unification and consistency by many analysts who have reviewed the new mechanism.

It i

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

s still too soon to determine how lenders of credit will adapt to and accept the new scoring method. However

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

it’s great news for consumers who are tired of being confused when looking at three reports containing exac

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ly the same information and a different end-number resulting from differing calculation methods and formulas

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/92081/adviceyou-VantageScore-Sheds-New-Light-on-Consumer-Creditworthiness.html">VantageScore Sheds New Light on Consumer Creditworthiness</a>

BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/92081/adviceyou-VantageScore-Sheds-New-Light-on-Consumer-Creditworthiness.html]VantageScore Sheds New Light on Consumer Creditworthiness[/url]

Unless you've been living under a rock for the past five years, you'll have heard of Paypal.

Tags

Links

Advice You - VantageScore Sheds New Light on Consumer Creditworthiness

Related Articles: